Yongke zhang

Company: IASO BioTherapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Evaluating Safety & CMC Expectations between Different Cell Therapy Types & Autoimmune Indications

Moderator – Fred Aslan, Chief Executive Officer, Artiva Biotherapeutics 8:30 am

• Discussing the advantages and disadvantages of different cell therapy modalities when meeting CMC expectations • Understanding safety parameters that need to be demonstrated and how those may differ in various autoimmune indications • What are some of the standards that are set or need to be set for cell therapies to advance in the…Read more

day: Day Two AM

Looking Beyond CD19 Antigens for Selective Depletion 1:30 pm

• Exploring antigens such as BCMA, BAFF, CD20, and CD90 to improve the targeting of B-cells • Can we combine targeting of different antigens for more therapy efficacy?Read more

day: Day One Track B, PM